69 related articles for article (PubMed ID: 1879084)
21. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
22. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
[TBL] [Abstract][Full Text] [Related]
23. Quantification of the nail fold capillary abnormalities in systemic sclerosis and Raynaud's syndrome.
Statham BN; Rowell NR
Acta Derm Venereol; 1986; 66(2):139-43. PubMed ID: 2424237
[TBL] [Abstract][Full Text] [Related]
24. Plasma or serum from patients with systemic sclerosis alters behaviour of normal erythrocytes.
Kovacs IB; Rustin MH; Thomas RH; Ridler C; Sowemimo-Coker SO; Kirby JD
Ann Rheum Dis; 1985 Jun; 44(6):395-8. PubMed ID: 4015202
[TBL] [Abstract][Full Text] [Related]
25. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon.
Mikhailidis DP; Hutton RA; Jeremy JY; Dandona P
Br Med J (Clin Res Ed); 1986 May; 292(6533):1461. PubMed ID: 3087473
[No Abstract] [Full Text] [Related]
26. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
[TBL] [Abstract][Full Text] [Related]
27. Circulating nerve growth factor in primary and secondary Raynaud's syndrome - results of a pilot study.
Klein-Weigel P; Gutsche-Petrak B; Humpel C; Riemekasten G; Ivanov S; Heidrich H
Vasa; 2009 Feb; 38(1):39-45. PubMed ID: 19229802
[TBL] [Abstract][Full Text] [Related]
28. Short-term effect of cold provocation on single-breath carbon monoxide diffusing capacity in subjects with and without Raynaud's phenomenon.
Gastaud M; Dolisi C; Bermon S; Gaudin P; Defauw G; Ardisson JL
Clin Exp Rheumatol; 1995; 13(5):617-21. PubMed ID: 8575140
[TBL] [Abstract][Full Text] [Related]
29. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma.
Freedman RR; Girgis R; Mayes MD
J Rheumatol; 1999 Nov; 26(11):2386-8. PubMed ID: 10555897
[TBL] [Abstract][Full Text] [Related]
30. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
Mavrikakis ME; Lekakis JP; Papamichael CM; Stamatelopoulos KS; Kostopoulos ChC; Stamatelopoulos SF
Int J Vitam Nutr Res; 2003 Feb; 73(1):3-7. PubMed ID: 12690904
[TBL] [Abstract][Full Text] [Related]
31. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
[TBL] [Abstract][Full Text] [Related]
32. Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis.
Blaise S; Maas R; Trocme C; Kom GD; Roustit M; Carpentier PH; Cracowski JL
J Rheumatol; 2009 May; 36(5):984-8. PubMed ID: 19332631
[TBL] [Abstract][Full Text] [Related]
33. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine.
Dooley A; Gao B; Bradley N; Abraham DJ; Black CM; Jacobs M; Bruckdorfer KR
Rheumatology (Oxford); 2006 Jun; 45(6):676-84. PubMed ID: 16399843
[TBL] [Abstract][Full Text] [Related]
34. [Hemodynamic response of the digital artery to heat and cold in normal subjects, in systemic scleroderma and in Raynaud's disease].
Vayssairat M; Mathieu JF; Housset E
J Mal Vasc; 1984; 9(1):7-10. PubMed ID: 6707534
[TBL] [Abstract][Full Text] [Related]
35. [The effect of membrane-bound calcium on the activity of adenosine triphosphatase from erythrocytes and erythrocyte permeability for monovalent cations].
Orlov SN; Shevchenko AS
Biokhimiia; 1978 Feb; 43(2):208-15. PubMed ID: 148300
[TBL] [Abstract][Full Text] [Related]
36. An improved filtration rate for measuring red cell deformability.
Sowemimo-Coker SO; Kovacs IB; Turner P; Kirby JD
Biorheology Suppl; 1984; 1():249-53. PubMed ID: 6591983
[TBL] [Abstract][Full Text] [Related]
37. Serum levels of tissue inhibitor of metalloproteinases 2 in systemic sclerosis: a preliminary study.
Dziankowska-Bartkowiak B; Waszczykowska E; Łuczyńska M; Zalewska A; Sysa-Jedrzejowska A
Med Sci Monit; 2002 Feb; 8(2):CR108-12. PubMed ID: 11859283
[TBL] [Abstract][Full Text] [Related]
38. Difficulty in detecting reperfusion injury increment in oxidative stress among patients with primary Raynaud's phenomenon and systemic sclerosis.
Herrick AL; Rieley F; Braganza JM; Jayson MI
J Rheumatol; 1995 Feb; 22(2):374-5. PubMed ID: 7738971
[No Abstract] [Full Text] [Related]
39. Prostacyclin increases filterability of normal and rigidified human red blood cells in vitro.
Kovacs IB; O'Grady J
Agents Actions; 1984 Feb; 14(2):306-10. PubMed ID: 6424425
[TBL] [Abstract][Full Text] [Related]
40. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis.
Herrick AL; Rieley F; Schofield D; Hollis S; Braganza JM; Jayson MI
J Rheumatol; 1994 Aug; 21(8):1477-83. PubMed ID: 7983650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
